Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Non Operating Income (2016 - 2025)

IGC Pharma (IGC) has disclosed Non Operating Income for 12 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 2406.98% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 1548.0% increase, with the full-year FY2025 number at $325000.0, up 127.27% from a year prior.
  • Non Operating Income was $1.1 million for Q3 2025 at IGC Pharma, up from $306000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.1 million in Q3 2025 to a low of -$7000.0 in Q4 2022.
  • A 5-year average of $125736.8 and a median of $32000.0 in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: plummeted 275.0% in 2022, then soared 2971.43% in 2025.
  • IGC Pharma's Non Operating Income stood at $4000.0 in 2021, then tumbled by 275.0% to -$7000.0 in 2022, then soared by 557.14% to $32000.0 in 2023, then skyrocketed by 53.12% to $49000.0 in 2024, then soared by 2100.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non Operating Income are $1.1 million (Q3 2025), $306000.0 (Q2 2025), and $215000.0 (Q1 2025).